|

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

RECRUITINGN/ASponsored by University Hospital, Toulouse
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Toulouse
Started2023-09-28
Est. completion2026-03-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05945524

Summary

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* With multiple myeloma
* Who receive Teclistamab
* Consent form signed

Exclusion Criteria:

* Patient under legal protection

Conditions2

CancerMultiple Myeloma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.